Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070222 | 0.79 | L3MBTL1 (0.46) | TRIM24TRIM33L3MBTL1ALDH1A1NFE2L2 | |
| SCHEMBL18352991 | 0.76 | LMNA (0.37) | SLC22A12L3MBTL1NFE2L2LMNASMN1; SMN2 | |
| SCHEMBL5061249 | 0.76 | TRIM24 (0.38) | TRIM24TRIM33L3MBTL1ALDH1A1NFE2L2 | |
| SCHEMBL3073167 | 0.75 | TRIM24 (0.35) | TRIM24TRIM33L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL19410840 | 0.75 | NPC1 (0.38) | TRIM24TRIM33ALDH1A1KMT2ALMNA | |
| SCHEMBL5490785 | 0.73 | L3MBTL1 (0.34) | SLC22A12L3MBTL1ALDH1A1KMT2ACYP2A6 | |
| SCHEMBL80776 | 0.72 | TRIM24 (0.38) | TRIM24TRIM33ALDH1A1NFE2L2KMT2A | |
| SCHEMBL1475053 | 0.72 | SLC22A12 (0.33) | SLC22A12 | |
| SCHEMBL3074012 | 0.72 | NOS3 (0.47) | SLC22A12ALDH1A1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL15413736 | 0.72 | TRIM24 (0.38) | TRIM24TRIM33SLC22A12L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-7396840-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7084155-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2006-08-01 | — | — | US | disclosed |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-06-15 | — | — | US | disclosed |
| US-6864265-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2005-03-08 | — | — | US | disclosed |
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-04 | — | — | US | disclosed |
| CN-1457339-A | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2003-11-19 | — | — | CN | disclosed |
| EP-1317445-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002022600-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | TRIM24 1715/4885TRIM33 2273/4885SLC22A12 1154/4885 |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | CXCR4, CCR5, CXCR3 | TRIM24 1320/4885TRIM33 2609/4885SLC22A12 1081/4885 |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | TRIM24 1715/4885TRIM33 2273/4885SLC22A12 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.